The virologic-failure rate difference was higher in ECHO trial (11.0% vs 4.4%) than in THRIVE (7.1% vs 5.3%), and there's no explanation for this either.
The disparity between the VF deltas of the two trials wasn’t statsig, as far as I know. It looks like routine statistical noise.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.